Enhanced Recovery after Surgery (ERAS) Program for Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery with or without HIPEC: A Systematic Review and a Meta-Analysis.

Autor: Robella, Manuela, Tonello, Marco, Berchialla, Paola, Sciannameo, Veronica, Ilari Civit, Alba Maria, Sommariva, Antonio, Sassaroli, Cinzia, Di Giorgio, Andrea, Gelmini, Roberta, Ghirardi, Valentina, Roviello, Franco, Carboni, Fabio, Lippolis, Piero Vincenzo, Kusamura, Shigeki, Vaira, Marco
Předmět:
Zdroj: Cancers; Feb2023, Vol. 15 Issue 3, p570, 15p
Abstrakt: Simple Summary: Cytoreductive surgery and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) represent a promising treatment strategy for the management of selected cases of peritoneal cancer, but it's still burdened by significant morbidity and prolonged hospital stay. Herein, the review of the impact of ERAS program on length of stay, postoperative complications and readmission rate in patients undergoing cytoreductive surgery with or without HIPEC for peritoneal surface malignancies. Enhanced recovery after surgery (ERAS) program refers to a multimodal intervention to reduce the length of stay and postoperative complications; it has been effective in different kinds of major surgery including colorectal, gynaecologic and gastric cancer surgery. Its impact in terms of safety and efficacy in the treatment of peritoneal surface malignancies is still unclear. A systematic review and a meta-analysis were conducted to evaluate the effect of ERAS after cytoreductive surgery with or without HIPEC for peritoneal metastases. MEDLINE, PubMed, EMBASE, Google Scholar and Cochrane Database were searched from January 2010 and December 2021. Single and double-cohort studies about ERAS application in the treatment of peritoneal cancer were considered. Outcomes included the postoperative length of stay (LOS), postoperative morbidity and mortality rates and the early readmission rate. Twenty-four studies involving 5131 patients were considered, 7 about ERAS in cytoreductive surgery (CRS) + HIPEC and 17 about cytoreductive alone; the case histories of two Italian referral centers in the management of peritoneal cancer were included. ERAS adoption reduced the LOS (−3.17, 95% CrI −4.68 to −1.69 in CRS + HIPEC and −1.65, 95% CrI −2.32 to –1.06 in CRS alone in the meta-analysis including 6 and 17 studies respectively. Non negligible lower postoperative morbidity was also in the meta-analysis including the case histories of two Italian referral centers. Implementation of an ERAS protocol may reduce LOS, postoperative complications after CRS with or without HIPEC compared to conventional recovery. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje